+39 02 610346.1 - info@newron.com

Investors and Media

Investors and Media

Newron Pharmaceuticals is headquartered in Bresso, Italy and its shares are listed on SIX Swiss Exchange under the ticker symbol NWRN. Newron is committed to providing reliable and transparent information about our business in an open and timely manner. This area contains investment and shareholder information, including our latest share price, key financial data and presentations and webcasts.

 

Newron newssee all

May 17 2017

Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age

 

May 12 2017

Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago® (safinamide)

 

April 11 2017

Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada

April 10 2017

ZAMBON LAUNCHES XADAGO® (safinamide) IN PORTUGAL For patients With mid- to late-stage Parkinson’s Disease

 

April 05 2017

Meiji Seika and Eisai enter into a collaboration for the development and commercialization of safinamide in Parkinson’s disease for Japan and Asia

Stock information

Download centre

Email alerts

 

 

 

 

 

Upcoming Eventssee all

German Equity Forum 2017

Nov, 27-29, 2017 - Frankfurt

Jefferies 2017 London Healthcare Conference

Nov, 15-16, 2017 - Waldorf Hilton, London

Investora 2017

Sept. 20-21, 2017 - Zurich, CH